Home > Healthcare > Medical Devices > Therapeutic Devices > Patient-controlled Analgesic Pumps Market

Patient-controlled Analgesic Pumps Market Analysis

  • Report ID: GMI7971
  • Published Date: Jan 2024
  • Report Format: PDF

Patient-controlled Analgesic Pumps Market Analysis

The market by type is segmented into electronic and wireless and mechanical segments. The electronic and wireless segment accounted for majority revenue share and was valued at around USD 306.6 million revenue in 2023.
 

  • The integration of electronic and wireless features enables remote monitoring of PCA pump usage, allowing healthcare providers to track patient responses and step-in in real-time in case of any concerns. Additionally, these capabilities facilitate integration with telehealth platforms, enabling virtual consultations and remote adjustments to pain management plans.
     
  • Remote monitoring enhances patient care, allows for timely interventions, and supports telehealth initiatives, especially valuable in situations where in-person visits are challenging.
     
  • Moreover, electronic and wireless capabilities enable real-time data collection on patient’s pain levels, pump usage, and system alerts. Real-time data analytics contribute to evidence-based decision-making, personalized pain management, and continuous improvement in patient outcomes.
     
Patient-controlled Analgesic Pumps Market, By Application (2023)

Based on application, the patient-controlled analgesic pumps market is categorized into oncology, diabetes, hematology, gastroenterology, and other applications. The oncology segment accounted for around 33.9% market share in 2023 and is anticipated to witness significant growth during the forecast period.
 

  • The increased global prevalence of cancer is an important driving factor for PCA pump growth in the oncology area. As the number of cancer cases increases, there is a greater demand for effective pain management treatments, and PCA pumps provide a patient-centered approach to pain control therapy. For instance, according to American Cancer Society, Inc. over 1.9 million new cancer cases were diagnosed in the U.S. in 2023.
     
  • Additionally, patient-controlled analgesic pumps offer a non-invasive method of pain control, thus, reducing the need for repeated injections or nurse-administered medications. This is particularly beneficial for oncology patients who may already be undergoing various invasive treatments, thereby leading to the segmental growth.
     

The patient-controlled analgesic pumps market by end-use is categorized into hospitals, specialty clinics, ambulatory surgical centers, and other end-users. The hospitals segment accounted for over USD 236.6 million revenue size in 2023.
 

  • Hospitals prioritize patient-centric care, and PCAPs align with this approach by empowering patients to actively participate in their pain management. The ability to control pain on-demand contributes to improved patient satisfaction and overall experience during hospitalization.
     
  • Furthermore, the ability of patients to self-administer pain medication through PCAPs contributes to higher levels of patient satisfaction. Empowering patients to manage their pain can positively impact their overall perception of care received in the hospital.
     
North America Patient-controlled Analgesic Pumps Market, (USD Million)

North America patient-controlled analgesic pumps market accounted for USD 183.3 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

  • Chronic pain problems, such as those associated with musculoskeletal diseases, surgical recovery, and cancer, are notably prevalent in North America. PCA pumps are used to efficiently control pain in these applications that contributes to the demand for these devices. For instance, according to Centers for Disease Control and Prevention, in 2021, over 20.9% of U.S. adults (51.6 million) reported chronic pain, while 6.9% (17.1 million) experienced high-impact chronic pain.
     
  • Furthermore, North America boasts advanced healthcare infrastructure, including well-equipped hospitals and healthcare facilities. This infrastructure supports the adoption of advanced medical technologies, including PCAPs, in both inpatient and outpatient settings, leading to the regional growth.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Patient-controlled analgesic pumps industry reached USD 453.9 million in revenue in 2023 and is projected to be worth USD 697.4 million by 2032 driven by the increasing number of surgical procedures and the ongoing advancements in pain management technologies

The electronic and wireless segment generated USD 306.6 million in 2023 and is projected to gain significant traction through 2032 due to the strong need to enable remote monitoring and facilitate integration with telehealth platforms.

North America patient-controlled analgesic pumps industry size was USD 183.3 million in 2023 and is estimated to exhibit robust growth through 2032 driven by the growing prevalence of chronic pain problems and the presence of an advanced healthcare infrastructure in the region.

Some leading companies engaged in the market are B. Braun Medical Inc., Abbott Laboratories, Ace-medical, Becton, Dickinson and Company, Changzhou Medical Bioengineering Co., Ltd., Fresenius SE & Co. KGaA, Henan Tuoren Medical Device Co., Ltd., ICU Medical, Inc., Micrel Medical Devices SA, and SCW MEDICATH LTD.

Patient-controlled Analgesic Pumps Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 213
  • Countries covered: 22
  • Pages: 120
 Download Free Sample